

Treatment of proven or suspected infections due to multi-drug resistant aerobic, carbapenem-resistant gram-negative pathogens that have demonstrated susceptibility

Disclaimer

This guideline is registered at North Central London (NCL) Joint Formulary Committee (JFC) and is intended solely for use by healthcare professionals to aid the treatment of patients within NCL. However, clinical guidelines are for guidance only, their interpretation and application remain the responsibility of the individual clinician. If in doubt, contact a senior colleague or expert. Clinicians are advised to refer to the manufacturer's current prescribing information before treating individual patients.

The authors and NCL JFC accept no liability for use of this information from this beyond its intended use. While we have tried to compile accurate information in this guideline, and to keep it updated in a timely manner, we cannot guarantee that it is fully complete and correct at all times. If you identify information within this guideline that is inaccurate, please report this to the admin.ncl-mon@nhs.net. If a patient is harmed as a consequence of following this guideline, please complete a local incident report and inform admin.ncl-mon@nhs.net.

This guideline should not be to used or reproduced for commercial or marketing purposes.

NCL JFC is funded by and provides advice to Acute Trusts and Clinical Commissioning Groups in NCL.

Document control

Date	Version	Amendments
November 2020	1.0	New document

Groups / Individuals who have overseen the development of this guidance:	NCL Consultant Microbiologists: Dr I Balakrishnan [RFL], Dr M Kelsey [WH], Prof P Wilson [UCLH], Dr S Jain [NNUH], Dr J Soothill [GOSH], Dr S Warren [RNOH] Ms P Panesar [UCLH Antimicrobial Pharmacist], Ms M Lanzman [RFL Antimicrobial Pharmacist], Ms M Kassam [JFC Support Pharmacist], Mr A Barron [JFC Support Pharmacist]
Groups which were consulted and have given approval:	NCL JFC
File name:	5_Treatment_of_mdr_carbapenem_resistant_gram_negative_pathogens.pdf
Version number:	1.0
Available on:	https://www.ncl-mon.nhs.uk/wp-content/uploads/Guidelines/5_Treatment_of_mdr_carbapenem_resistant_gram_negative_pathogens.pdf
Disseminated to:	All Trusts and CCGs in NCL
Equality impact assessment:	Low
NCL Joint Formulary Committee Approval date:	November 2020
Review date:	November 2023

Treatment of proven or suspected infections due to multi-drug resistant aerobic, carbapenem-resistant gram-negative pathogens that have demonstrated susceptibility

Colour coding reflects probability of sensitivity¹ and not the formulary preference:

- **Green:** more than 80% susceptible
- **Yellow:** 30-80% susceptible
- **Red:** intrinsically resistant or <30% susceptible

Formulary preference is provided in text within each colour coded box. If an organism is susceptible to an **Amber** antibiotic, it should be considered alongside **Green** antibiotics with treatment choice dependent on patient factors and cost. Please note chloramphenicol and co-trimoxazole may have activity for some carbapenem-resistant gram-negative pathogens.

Antibiotic	Cost	KPC (class A)	MBL (class B)	OXA-48 (class D)	MDR Pseudomonas
Colistin (not monotherapy*)	£				
Tigecycline (not monotherapy*)	£	Not preferred due FDA alert (increased risk of mortality) and caution in children <8 years ^{2,3}	Not preferred due FDA alert (increased risk of mortality) and caution in children <8 years ^{2,3}	Not preferred due FDA alert (increased risk of mortality) and caution in children <8 years ^{2,3}	
Meropenem/vaborbactam	££	Preferred agent			
Fosfomycin IV (not monotherapy*)	££				
Ceftazidime/avibactam	£££	Not preferred due to high cost		Preferred agent	
Aztreonam + Ceftazidime/avibactam	£££	Non-formulary	Preferred agent	Non-formulary	
Ceftolozane/tazobactam	££££				Preferred where other agents are not suitable
Cefiderocol	££££££	Non-formulary	Preferred where other agents are not suitable	Non-formulary	Non-formulary

* Combination with meropenem is appropriate provided MIC for meropenem is ≤8.

References:

1. TammaPD, Hsu AJ. Journal of the Pediatric Infectious Diseases Society 2019;8(3):251–60
2. Food and Drug Administration. FDA Drug Safety Communication: FDA warns of increased risk of death with IV antibacterial Tygacil (tigecycline) and approves new Boxed Warning. September 2013 ([link](#))
3. eMC: Tigecycline 50 mg powder for solution for infusion ([link](#))